Visualizing Updates in Melanoma Management: Novel Combinations, Development, and Best Practices in Sequencing Therapy
The ACTIVATE Initiative Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies
This activity is designed to meet the educational needs of both community based and academic oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician’s assistants to ensure confidence in the management of advanced melanoma.
An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician’s assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immuno-therapy approaches in advanced melanoma.